INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		39-18 APPLICA	37 O C 09	N/367,261						
		BLAKE et al FILING DATE August 13, 1999								
	-			J.S. PATENT DOCUMENTS		·				
*EXAM	AINER						FILING	DATE		
INI	JAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPR	OPRIATE		
_12	4	5086068	2/1992	Raleigh et al						
9/1		5387692	2/1995	Riley et al						
						<u> </u>				
			FC	PREIGN PATENT DOCUMENTS						
		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO		
		0 650 763	6/1995	EP		i				
		WO 96 25147	8/1996	PCT						
		OTHER DOC	UMENTS (including Author, Title, Date, Pertin	ent pages,	etc.)		<u> </u>		
30	1	glutathionyl conjugate ABSTRACTS, VOL. 1 (1989).	in biologica	ox properties of naphthazarin (5,8-dihy al reactions: one- and two-electron enz , 12 March 1990, Columbus, Ohio, US	cymic reduction; and ARCH.	on", CHEM BIOCHEM	ICÁL . BIOPH	IYS.		
		Firestone et al, "Nitro heterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells", <i>J. MED. CHEM</i> , (1991), 34(9).								
		melphalan prodrugs", CANCER RESEARCH	<i>EIGHTY-Ei</i> I, San Dieg	rodrugs: Redox-activation of conform IGHTH ANNUAL MEETING OF THE A o, California, USA, April 12-16, 1997. ESEARCH ANNUAL MEETING (38 (0	AMERIČAN A PROCEEDI	ASSOCIATI NGS OF TH	ON FOR	7		
		Mehta et al, "Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP", ANTI-CANCER DRUG DES. (1995), 10(3), 227-41.								
				s and binding of the bioreductive prob vol. 72, 1995, pages 1462-1468.	e for hypoxia	, NITP: eff	ect of ro	ute of		
y de		Berglund, "Bioreductive" 1987.	e Heterosu	bstituted Quinone Antitumor Drug Del	ivery Agents'	", DATABA	SE DISS	ABS,		
	ļ									
*====		 	D. A) Data Caracida val			100	,		
*Exar		1 /5	Best	Date Considered	<u> </u>	7-13-	i COC			
examination copy of	er: Initial i this form	if reference considered, whether or with next communication to applicat	not citation is in tion.	conformance with MPEP 609; Draw line through citation	on if not in conform	nance and not or	onsidered. I	nclude		

Form PTO-FB-A820 (Also PTO-1449)

09/367261 510 Rec'd PCT/PTO 1 3 AUG 1999

Form PTO-FB-A820 (Also PTO-1449)

INFOR	RMATION DISCLOSURE CITATION	39-187	Unk	Unknown				
(U	se several sheets if necessary)	BLAKE et al FILINGUATE GROUP August 13, 1999						
		U.S	. PATENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
150	5086068	2/1992	Raleigh et al					
B	5387692	2/1995	Riley et al					
		FORI	EIGN PATENT DOCUMENTS	L	L	<u></u>		
			***			TRANS	LATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	МО	
	0 659 763	6/1995	EP					
	WO 96 25147	8/1996	PCT					
			cluding Author, Title, Date, Pertine					
3/	glutathionyl conjugate ABSTRACTS, VOL. 1 (1989).	in biological re 12, NO. 11, 12 neterocycle re	properties of naphthazarin (5,8-dihyd eactions: one- and two-electron enzy 2 March 1990, Columbus, Ohio, US; duction as a paradigm for intramolect	mic reducti and ARCH	ion", CHEM I. BIOCHEM	ICAL I. BIOPH	IYS.	
	Chikhale et al, "Tumor melphalan prodrugs", CANCER RESEARCH ASSOCIATON FOR C	targeted prod EIGHTY-EIGH I, San Diego, CANCER RES	Ings: Redox-activation of conforma Ings: Redox-activation of conforma In Annual MEETING OF THE AI California, USA, April 12-16, 1997. I EARCH ANNUAL MEETING (38 (0). Cactivated hypoxia probes and post-	MERIČAN A PROCEEDA 1997. 432	ASSOCIATI INGS OF TI 2-433.	ON FOR HE AME	R RICAN	
	NITP", ANTI-CANCEF Hodgkiss et al, "Pharm	R DRUG DES. nacokinetics a	(1995), 10(3), 227-41. nd binding of the bioreductive probe					
PD			I. 72, 1995, pages 1462-1468. Lituted Quinone Antitumor Drug Deliv	ery Agents	", DATABA	SE DISS	ABS,	
								
*Examiner	13	anh	Date Considered	6-3	3-) CO	>		
	I if reference considered, whether or		formance with MPEP 609; Draw line through citation	if not in confor	mance and not o	onsidered.	Include	